



Enz-64(CIP)

IFW\$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ilan et al

Serial No. 10/675,980

Filed: September 30, 2003

Title: GLUCOCEREBROSIDE TREATMENT
OF DISEASE

Group Art Unit: 1648

Examiner: Emily M. Le

527 Madison Avenue, 9th Floor
New York, New York 10022
June 23, 2004

FILED VIA EXPRESS MAIL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.56 & 1.97-1.98


Dear Sirs:

Pursuant to the provisions of 37 C.F.R. §§1.97-1.98, and in full compliance with their duty of disclosure under 37 C.F.R. §1.56, Applicants, through their attorney, are bringing the following five (5) documents to the attention of the U.S. Patent and Trademark Office and the Examiner handling their above-identified application:

06/28/2004 AWONDAF1 00000001 051135 10675980
01 FC:1806 180.00 DA

Enz-64(CIP)

Ilan et al
Serial No.: 10/675,980
Filed: September 30, 2003
Page 2 [Second Information Disclosure Statement
-June 23, 2004]

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No.: <u>EL705916932US</u>	
Deposit Date:	<u>June 23, 2004</u>
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.110 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
 Ronald C. Fedus Reg. Exhibit 32,567	<u>6/23/04</u> Date

1. Fredman, P., et al., International Patent Application No. WO 99/33475, published July 8, 1999 [Exhibit 1];
2. Koezuka, Y., et al., European Patent Application No. 0 957 161 A1, published November 17, 1999 [Exhibit 2];
3. Margalit, M., et al., "Glucocerebroside Treatment Ameliorates Con-A Hepatitis by Inhibition of NKT Lymphocytes: A New Immunomodulatory Tool," Hepatology 38:163A (2003) [Exhibit 3];
4. Taniguchi, M., et al., European Patent Application No. 0 988 860 A1, published March 29, 2000 [Exhibit 4];
5. Vo-Hoang, Y., et al., International Patent Application No. WO 03/093287 A1, published November 13, 2003 [Exhibit 5];

The five (5) foregoing references (numbers 1-5) were cited in partial European Search Report received in a Communication from the European Patent Office dated June 9, 2004 relating to the corresponding European Application No. 04 00 4583.3, filed February 27, 2004.

A completed Form PTO-1449 listing the 5 above-submitted documents is also attached hereto as Exhibit 6.

By this voluntary citation of art, Applicants and their attorney are requesting that the documents be made of record in the present application.

The above citation of documents is not a representation that these documents constitute a complete or exhaustive listing, nor that the above listing necessarily includes the closest or most relevant documents, nor are these documents necessarily a complete listing of all documents known to Applicants or their attorney. It is simply a voluntary citation of documents made in good faith, which is not intended to serve in any way as a substitute for the Examiner's own search.


In view of the general and specific features described and claimed in the present application, Applicants respectfully submit that the present invention is

neither disclosed nor suggested by the documents referred to above and is thus patentably distinct thereover. Furthermore, Applicants do not believe, and do not submit, by the citation of these references, that these documents, either by themselves or in combination with other documents, render the invention *prima facie* obvious under the duty of disclosure rules.

Applicants respectfully request that the Examiner make the above-submitted documents of record in the instant application. Applicants further request that the Examiner consider these documents as any of them may relate to the instant application.


The fee under 37 C.F.R. §1.17(p) for filing this Information Disclosure Statement is \$180.00. The Patent and Trademark Office is hereby authorized to charge the amount of this fee (and any other fees in connection with this IDS) to Deposit Account No. 05-1135, or to credit any overpayment thereto.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Natalie Bogdanos
Registration No. 51,480
Attorneys for Applicants

ENZO LIFE SCIENCES, INC.
c/o Enzo Biochem, Inc.
527 Madison Avenue, 9th Floor
New York, New York 10022
Tel. (212) 583-0100



FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$ 180.00)

Complete if Known

Application Number	10/675,980
Filing Date	September 30, 2003
First Named Inventor	Ilan
Examiner Name	Emily M. Le
Art Unit	1648
Attorney Docket No.	Enz-64(CIP)

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit
Account
Number
Deposit
Account
Name

05-1135

Enzo Biochem

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Credit any overpayments☐ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)					(\$ 0)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	-20** =	X	
Independent Claims	-3** =	X	
Multiple Dependent			

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$ 0)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 180.00)

SUBMITTED BY

(Complete if applicable)

Name (Print/Type)

Ronald C. Fedus

Registration No.
(Attorney/Agent)

32,567

Telephone 212-583-0100

Signature

Date

6/23/04

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Form PTO-1449 U.S. Department of Commerce

(REV. 8-83) Patent and Trademark Office

Atty. Docket No.
ENZ-64(CIP)

Serial No. 10/675,980

INFORMATION DISCLOSURE CITATION
(use several sheets if necessary)

JUN 24 2004

Applicants: Ilan, et al

Filed: Sep. 30, 2003

Group: 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	TRAN- SLATION YES NO
	WO 9 9 3 3 4 7 5	7/8/99	Fredman, et al	A1		
	EP 0 9 5 7 1 6 1	11/17/99	Koezuka, et al	A1		
	EP 0 9 8 8 8 6 0	3/29/00	Taniguchi, et al	A1		
	WO 0 3 9 3 2 8 7	11/13/03	Vo-Hoang, et al	A1		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Margalit, M., et al., "Glucocerebroside Treatment Ameliorates Con-A Hepatitis by Inhibition of NKT Lymphocytes: A New Immunomodulatory Tool," Hepatology 38:163A (2003)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.